REGENXBIO Inc. (RGNX)
Automate Your Wheel Strategy on RGNX
With Tiblio's Option Bot, you can configure your own wheel strategy including RGNX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RGNX
- Rev/Share 3.1209
- Book/Share 3.1235
- PB 2.542
- Debt/Equity 1.6608
- CurrentRatio 2.6649
- ROIC -0.3432
- MktCap 401947303.0
- FreeCF/Share -2.0562
- PFCF -3.7819
- PE -2.3068
- Debt/Assets 0.5105
- DivYield 0
- ROE -0.7829
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | RGNX | Barclays | -- | Overweight | -- | $37 | Jan. 28, 2026 |
| Downgrade | RGNX | Goldman | Buy | Neutral | $38 | $14 | Feb. 11, 2025 |
| Resumed | RGNX | Raymond James | -- | Outperform | -- | $27 | Feb. 7, 2025 |
| Resumed | RGNX | Raymond James | -- | Outperform | -- | $18 | Oct. 10, 2024 |
News
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: February 24, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Feb. 24, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against REGENXBIO Inc. (“Regenxbio” or “the Company”) (NASDAQ: RGNX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 9, 2022 and January 27, 2026, inclusive (the “Class Period”), are encouraged to contact the firm before April 14, 2026.
Read More
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: February 23, 2026 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES, Feb. 23, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against REGENXBIO Inc. ("Regenxbio" or "the Company") (NASDAQ: RGNX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 9, 2022 and January 27, 2026, inclusive (the "Class Period"), are encouraged to contact the firm before April 14, 2026.
Read More
REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX
Published: February 23, 2026 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES, Feb. 23, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against REGENXBIO Inc. ("Regenxbio " or "the Company") (NASDAQ: RGNX ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of RGNX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.
Read More
ROSEN, LEADING TRIAL ATTORNEYS, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX
Published: February 22, 2026 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - February 22, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed.
Read More
RGNX Stockholder Alert: Robbins LLP Remind Investors of the Class Action Lawsuit Against REGENXBIO, Inc.
Published: February 20, 2026 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired REGENXBIO, Inc. (NASDAQ: RGNX) securities between February 9, 2022 and January 27, 2026. REGENXBIO is a clinical-stage biotechnology company providing gene therapies that deliver functional genes to cells with genetic defects in the United States.
Read More
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: February 20, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Feb. 20, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against REGENXBIO Inc. (“Regenxbio” or “the Company”) (NASDAQ: RGNX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 9, 2022 and January 27, 2026, inclusive (the “Class Period”), are encouraged to contact the firm before April 14, 2026.
Read More
RGNX INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026
Published: February 19, 2026 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In REGENXBIO To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in REGENXBIO between February 9, 2022 and January 27, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Feb. 19, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against REGENXBIO Inc. ("REGENXBIO" or the "Company") (NASDAQ: …
Read More
Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Published: February 19, 2026 by: GlobeNewsWire
Sentiment: Neutral
New class action for REGENXBIO (RGNX) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of Apr. 14, 2026.
Read More
Portnoy Law Firm Announces Class Action on Behalf of REGENXBIO, Inc. Investors
Published: February 19, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises REGENXBIO, Inc., (“REGENXBIO” or the "Company") (NASDAQ: RGNX) investors of a class action on behalf of investors that bought securities between February 9, 2022 and January 27, 2026, inclusive (the “Class Period”). REGENXBIO investors have until April 14, 2026 to file a lead plaintiff motion.
Read More
The Gross Law Firm Notifies REGENXBIO Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - RGNX
Published: February 19, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK, Feb. 19, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of REGENXBIO Inc. (NASDAQ: RGNX). Shareholders who purchased shares of RGNX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
REGENXBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against REGENXBIO Inc. and Encourages Investors to Contact the Firm
Published: February 18, 2026 by: GlobeNewsWire
Sentiment: Neutral
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In REGENXBIO (RGNX) To Contact Him Directly To Discuss Their Options
Read More
RGNX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026
Published: February 17, 2026 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In REGENXBIO To Contact Him Directly To Discuss Their Options
Read More
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX
Published: February 17, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 14, 2026.
Read More
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of REGENXBIO Inc. (RGNX) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm
Published: February 17, 2026 by: GlobeNewsWire
Sentiment: Neutral
ATLANTA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against REGENXBIO Inc. (NASDAQ: RGNX). The lawsuit alleges that Defendants issued false and misleading statements and/or failed to disclose material adverse facts concerning the efficacy and safety of its RGX-111 trial study, causing Plaintiff and other shareholders to purchase REGENXBIO's securities at artificially inflated prices.
Read More
Portnoy Law Firm Announces Class Action on Behalf of REGENXBIO, Inc. Investors
Published: February 17, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Feb. 17, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises REGENXBIO, Inc., (“REGENXBIO” or the "Company") (NASDAQ: RGNX) investors of a class action on behalf of investors that bought securities between February 9, 2022 and January 27, 2026, inclusive (the “Class Period”). REGENXBIO investors have until April 14, 2026 to file a lead plaintiff motion.
Read More
Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the REGENXBIO, Inc. Securities Class Action Lawsuit
Published: February 16, 2026 by: Business Wire
Sentiment: Neutral
SAN DIEGO--(BUSINESS WIRE)---- $RGNX #biotechnology--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired REGENXBIO, Inc. (NASDAQ: RGNX) securities between February 9, 2022 and January 27, 2026. REGENXBIO is a clinical-stage biotechnology company providing gene therapies that deliver functional genes to cells with genetic defects in the United States. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800).
Read More
Rosen Law Firm Urges REGENXBIO, Inc. (NASDAQ: RGNX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
Published: February 16, 2026 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the “Class Period”). REGENXBIO is a clinical-stage biotechnology company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that REGENXBIO, Inc.
Read More
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against REGENXBIO Inc. (RGNX)
Published: February 16, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 16, 2026 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of Maryland on behalf of all persons or entities who purchased or otherwise acquired REGENXBIO Inc. (“REGENXBIO” or the “Company”) (NASDAQ: RGNX) securities between February 9, 2022 and January 27, 2026, inclusive (the “Class Period”).
Read More
RGNX Investors Have Opportunity to Join REGENXBIO Inc. Fraud Investigation with the Schall Law Firm
Published: February 03, 2026 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)---- $RGNX--RGNX Investors Have Opportunity to Join REGENXBIO Inc. Fraud Investigation with the Schall Law Firm.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of REGENXBIO Inc. - RGNX
Published: February 03, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of REGENXBIO Inc. (“Regenxbio” or the “Company”) (NASDAQ: RGNX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
RGNX ALERT: Levi & Korsinsky Investigates REGENXBIO Inc. for Possible Securities Fraud Violations
Published: January 29, 2026 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - January 29, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into REGENXBIO Inc. ("REGENXBIO Inc.") (NASDAQ: RGNX) concerning potential violations of the federal securities laws. On January 28, 2026, Regenxbio disclosed via Form 8-K that the FDA placed clinical holds on its RGX-111 and RGX-121 programs following the identification of a tumor in a trial participant.
Read More
INVESTOR ALERT: Investigation of REGENXBIO Inc. (RGNX) by Holzer & Holzer, LLC
Published: January 28, 2026 by: GlobeNewsWire
Sentiment: Neutral
ATLANTA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether REGENXBIO Inc. (“REGENXBIO” or the “Company”) (NASDAQ: RGNX) complied with federal securities laws. On January 28, 2026, REGENXBIO announced it “received communication from the U.S. Food and Drug Administration (“FDA”) that the Company's Investigational New Drug applications for both its Phase I/II trial evaluating RGX-111 for Mucopolysaccharidosis type I and its Phase I/II/III trial of RGX-121 for Mucopolysaccharidosis type II were placed on clinical hold.” Following this news, the price of the Company's stock dropped.
Read More
Regenxbio (RGNX) Reports Q3 Loss, Beats Revenue Estimates
Published: November 06, 2025 by: Zacks Investment Research
Sentiment: Neutral
Regenxbio (RGNX) came out with a quarterly loss of $1.2 per share versus the Zacks Consensus Estimate of a loss of $1.38. This compares to a loss of $1.17 per share a year ago.
Read More
REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights
Published: October 29, 2025 by: PRNewsWire
Sentiment: Neutral
ROCKVILLE, Md. , Oct. 29, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, November 6, at 8:00 a.m.
Read More
REGENXBIO Inc. (RGNX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Published: September 08, 2025 by: Seeking Alpha
Sentiment: Neutral
REGENXBIO Inc. (NASDAQ:RGNX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 11:30 AM EDT Company Participants Curran Simpson - President, CEO & Director Steve Pakola - Executive VP & Chief Medical Officer Mitchell Chan - Executive VP & CFO Presentation Unknown Analyst Welcome, everyone, to this session of the Morgan Stanley Global Healthcare Conference. We're excited to have team from REGENX here.
Read More
FDA Extends Decision Date On Regenxbio's Gene Therapy Into Next Year
Published: August 19, 2025 by: Benzinga
Sentiment: Negative
The U.S. Food and Drug Administration (FDA) on Monday extended its review timeline for REGENXBIO Inc.'s RGNX Biologics License Application (BLA) for clemidsogene lanparvovec (RGX-121) for Mucopolysaccharidosis II (MPS II), also known as Hunter syndrome.
Read More
REGENXBIO Inc. (RGNX) Q2 2025 Earnings Call Transcript
Published: August 08, 2025 by: Seeking Alpha
Sentiment: Neutral
REGENXBIO Inc. (NASDAQ:RGNX ) Q2 2025 Earnings Call August 7, 2025 8:00 AM ET Company Participants Curran M. Simpson - President, CEO & Director Mitchell Chan - Executive VP & CFO Patrick J.
Read More
Regenxbio (RGNX) Reports Q2 Loss, Lags Revenue Estimates
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Regenxbio (RGNX) came out with a quarterly loss of $1.38 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to a loss of $1.05 per share a year ago.
Read More
REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy
Published: July 10, 2025 by: PRNewsWire
Sentiment: Neutral
Construct including CT domain demonstrated higher levels of microdystrophin protein, increased muscle force, and improved resistance to damage in mice lacking dystrophin REGENXBIO's next-generation investigational gene therapy, RGX-202, is the only microdystrophin construct that includes the CT domain Findings support the positive functional data seen in Phase I/II AFFINITY DUCHENNE® trial of RGX-202 ROCKVILLE, Md. , July 10, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the publication of preclinical results comparing a microdystrophin gene therapy construct that included the C-terminal (CT) domain to a microdystrophin construct without the CT domain.
Read More
Early Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, Longer
Published: June 05, 2025 by: Benzinga
Sentiment: Positive
RegenXBio Inc. RGNX revealed new interim data on Thursday from the Phase 1/2 AFFINITY DUCHENNE trial.
Read More
About REGENXBIO Inc. (RGNX)
- IPO Date 2015-09-17
- Website https://www.regenxbio.com
- Industry Biotechnology
- CEO Curran Simpson
- Employees 353